AGP Executive Report
Last update: 4 hours agoProstate Cancer Screening: Sweden’s Stockholm3 test (Karolinska Institute/A3P Biomedical) reported in Annals of Internal Medicine shows 90% sensitivity and 89% specificity for detecting aggressive prostate cancer (Grade Group ≥2), outperforming PSA alone (74% sensitivity at PSA ≥3 ng/ml). Cancer Research: EHA coverage highlights new lymphoma and CLL data, including TAILOR phase 2 results for dose-modified ibrutinib plus venetoclax in untreated CLL, with very high response rates and strong 12-month progression-free survival. Rare Disease Watch: Cogent Biosciences presented APEX trial updates for bezuclastinib in advanced systemic mastocytosis, reporting high response rates and major drops in disease markers like tryptase. AI for Health & Science: NVIDIA announced a record 35 AI supercomputers across Europe, explicitly backing healthcare research alongside climate and clean-energy work. Digital Health Infrastructure: Ericsson and Telia launched Digital Arena Sweden, a national test centre for 5G/6G and AI aimed at accelerating real-world trials for sectors including medtech. HPV Prevention Policy: MoHAP set out a national roadmap to eliminate HPV-related diseases, focusing on vaccination plus early detection and public awareness.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
